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Topical corticosteroids 
Topical corticosteroids (TCSs) continue to be the 
mainstay of atopic dermatitis (AD) treatment.[1,2] For 
more than four decades TCSs have provided effective 
flare control through their anti-inflammatory, 
antiproliferative, immunosuppressive and vasoconstrictive actions. 
They suppress the release of inflammatory cytokines and act on 
a variety of immune cells, including T lymphocytes, monocytes, 
macrophages, dendritic cells and their precursors. Various strengths 
and formulations of TCSs are available. The extent to which they 
induce cutaneous vasoconstriction and inhibit inflammation 
corresponds to their potency. 
The extensive use of TCSs in clinical practice is supported 
by an ever-expanding body of clinical trial data, which assists 
in providing physicians with sensible recommendations for the 
quantity, frequency, and duration of TCS therapy.[3,4] Preparations 
of very weak or moderate strength are used on the face and 
genital area, whereas those of moderate or potent strength are 
used on other areas of the body.[5] Patients should be educated 
about the different steroid potencies to minimise untoward side-
effects.[6]
The vehicle through which the active steroid is delivered plays an 
important role in absorption and can enhance its efficacy. Generally, 
ointments are more effective than creams, as the emollient action 
and occlusive effect result in better skin penetration. Ointments also 
require fewer preservatives; therefore, the potential for irritant and 
allergic reactions is lower. Wet wraps and application under occlusion 
enhance absorption of topical steroids. The various formulations of 
TCSs available are shown in Table 1.
The corticosteroid preparations currently available in South Africa 
(SA) are listed below according to potency, with the different 
formulations given in Table 2.
Topical steroids may be used for 10 - 14 days when the dermatitis is 
active, followed by ‘holidays’, with emollients only. TCSs may also be 
used in bursts of 3 - 7 days to treat exacerbations. This rationale may 
be extended to using potent TCSs for a few days to initiate control, 
followed by the use of a milder-potency TCS and/or an emollient.[7] 
For chronic lichenified eczema, frequent applications of potent steroids 
are required for much longer periods. A possible regimen for TCSs as 
maintenance treatment for stable disease is ‘weekend use’, when the 
product, combined with emollients, is applied on weekend days only, 
while continuing with emollients only during the rest of the week. 
The quantity of TCS that should be used is a common practical 
problem for patients. The fingertip unit is useful: the index finger 
from distal crease to fingertip approximates 0.5  g. This aids the 
monitoring of compliance and use. There is no clear evidence that a 
twice-daily application of TCS is better than a once-daily application. 
It may be justified to use once-daily corticosteroids as a first step in 
all patients with AD, thus reducing cost, improving compliance and 
reducing side-effects.
There is no convincing evidence for the superior clinical efficacy 
of corticosteroid-antibiotic combination products compared with 
corticosteroids alone. When the efficacy of TCSs is reduced, it is thought 
to be related to disease severity rather than corticosteroid resistance.[8]
There are many challenges regarding TCS use, especially in light 
of steroid abuse, misuse, phobia and side-effects. Adverse effects are 
well documented and it is important to recognise the side-effects, 
such as skin atrophy, telangiectasia, hypopigmentation, steroid acne, 
hirsutism, rosacea and contact sensitisation to the steroid itself. Skin 
atrophy is not a problem when TCSs are used correctly. 
Uncommon systemic effects are the suppression of the 
hypothalamic-pituitary-adrenal axis, growth retardation, 
tachyphylaxis, glaucoma, cataract formation and Cushing’s 
syndrome. Over recent years the risk of adverse effects of TCSs 
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has been reduced by optimising application 
protocols and using newer steroid 
preparations with improved risk/benefit 
ratios, e.g. prednicarbate, mometasone 
furoate, fluticasone and methylprednisolone 
aceponate. This improved risk/benefit ratio 
means that the products may be used at a 
younger age (from the age of four months) 
and for longer periods (for four weeks 
continuously in babies and three months 
in older children and adults). Should these 
drugs be required at a younger age and 
for longer periods, as is often the case, the 
benefit versus risk should be evaluated 
in each patient and the appropriate 
formulation carefully selected. Intermittent 
dosing should be used as far as possible.
The judicious use of TCSs would include 
short-term appropriate applications as 
initial monotherapy or in combination with 
other therapeutic agents that ideally possess 
complementing mechanisms of action. 
These drugs could be either systemic agents 
or topical agents, such as the newer topical 
calcineurin inhibitors (TCIs).[9]
Topical calcineurin 
inhibitors 
TCIs (pimecrolimus and tacrolimus) are 
complex macrocyclic compounds that result in 
selective inhibition of cytokine transcription 
in activated T cells. Pimecrolimus selectively 
targets T cells and mast cells. In contrast 
to tacrolimus, pimecrolimus has no effect 
on the differentiation, maturation and 
function of dendritic cells. Compared 
with corticosteroids, TCIs do not affect 
endothelial cells and fibroblasts and therefore 
do not induce skin atrophy.
TCIs are registered for short-term and 
non-continuous chronic treatment of 
moderate to severe AD in immunocompetent 
patients aged ≥2 years old.[10,11] Clinically, 
pimecrolimus lowers the incidence of flares 
and significantly reduces pruritus.
Both pimecrolimus and tacrolimus are 
safe and effective in reducing the severity of 
AD symptoms in children and adults. 
TCIs are frequently associated with a transient 
burning sensation of the skin, less so with 
pimecrolimus than tacrolimus.[12] TCIs are not 
associated with skin atrophy and are therefore 
useful for the face and intertriginous areas. 
This can be an advantage in long-term use, 
and tacrolimus ointment therapy additionally 
reverses corticosteroid-induced skin atrophy.
In January 2006, the US Food and Drug 
Administration (FDA) added a boxed 
warning to TCI labels noting that the long-
term safety of these agents has not been 
established. This warning was in response to 
widespread off-label use in infants (<2 years) 
and concerns about a potential cancer risk 
based on three factors: (i) a shared mechanism 
of action with systemic calcineurin inhibitors; 
(ii) animal toxicology studies; and (iii) rare 
post-marketing case reports of malignancy 
(skin cancer and lymphomas) (http://www.fda.
gov/). TCIs are not safe to use in pregnancy or 
during breastfeeding.
Use of phototherapy 
When topical modalities fail to control AD, 
phototherapy is the next option. Narrow-
band ultraviolet B (UVB) light is highly 
effective and has replaced broadband 
UVB for treating AD. Patients with 
acutely inflamed AD do not tolerate UV 
light well. Therefore, the initial treatment 
includes immunomodulators, such as 
cyclosporin or mycophenylate mofetil, or 
immunosuppressives, such as azathioprine or 
methotrexate. Once the acute inflammation 
has settled, UVB therapy may be instituted.[13]
Systemic therapy 
Narrow-band UVB, methotrexate and 
cyclosporin remain reasonable first-
line systemic treatments for AD, with 
mycophenylate and azathioprine as second-
line options.[14]
Systemic corticosteroids 
Systemic corticosteroids are frequently used 
for short-term therapy of severe AD, but 
their use is controversial.
The 2006 Practical Allergy (PRACTALL) 
consensus group guidelines (http://www.
onlinelibrary.wiley.com/doi/10.1111/j.1398-
9995.2006.01153.x/pdf) suggest that in 
the case of acute flare-ups, patients might 
benefit from a short course of systemic 
corticosteroids, but long-term use and use in 
children should be avoided.
Table 1. Available topical corticosteroid formulations
• Water-based lotions: to be used on acute wet dermatitis, scalps of babies, and hairy skin 
areas in adults 
• Alcohol-based lotions: to be used on scalps of older patients 
• Shampoo: to be used as short-contact applications for resistant scalp dermatitis in adults
• Creams: to be used on thin subacute lesions, thin skin areas, skin folds, under occlusion 
(e.g. nappies and occlusive dressings on the face)
• Ointments: to be used on dry subacute lesions
• Fatty ointments: to be used on thick chronic lichenified lesions and thick skin areas
Table 2. Topical corticosteroids available in South Africa
Corticosteroid Formulation
Lowest potency
0.5% hydrocortisone Cream, ointment
Low potency
1% hydrocortisone Cream, ointment
Moderate potency
Beclomethasone dipropionate Cream
Clobetasone butyrate Cream
Fluticasone propionate Cream, ointment
Hydrocortisone 17-butyrate Cream, lipocream, ointment, lotion, emulsifying lotion
Methylprednisolone acetonate 1% Milk, scalp solution, cream, ointment, fatty ointment 
Mometasone furoate Cream, ointment, lotion
Potent
Betamethasone valerate Cream, ointment, solution, scalp solution
Fluocinolone acetonide Cream, ointment, gel
Diflucortolone valerate Cream, fatty ointment, forte ointment
Very potent
Clobetasol propionate Cream, ointment, shampoo, scalp solution 
Bethametasone dipropionate Cream, ointment
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In the rare instances when these agents are 
prescribed, we prefer the use of prednisolone 
or prednisone at 1 - 2 mg/kg/d. To minimise 
rebound flares or recrudescence of disease 
after discontinuation of treatment, we 
favour tapering after initial control or 
if improvement is seen after the first 1 - 3 
weeks, typically tapering over a period of 
1 - 4 weeks, depending on the severity and 
course of the disease.[15]
Antibiotics 
Oral antibiotics do not benefit AD when 
used for skin that is not clinically infected, 
but infected dermatitis should be treated 
with penicillinase-resistant penicillins, 
cephalosporins or clindamycin.[16,17] 
Antifungals 
Malassezia sympodialis sensitisation plays 
an important role in AD in adults, especially 
in patients with head and neck dermatitis. 
IgE-mediated reactions to the fungus can be 
demonstrated in such patients. Randomised 
controlled trials (RCTs) with systemic 
itraconazole[18] and ketoconazole[19] showed 
significant benefit in such patients. 
Intravenous immunoglobulin 
This modality may be used as a last resort in 
children with severe refractory AD, and is 
supported by at least one RCT.[20]
Interferon gamma
This expensive treatment may be a useful 
modality for moderate to severe AD in 
children and adults who have a history 
of recurrent skin infections with herpes 
simplex, human papillomavirus or molluscum 
contagiosum.[21]
Biological drugs
Infliximab, efalizumab, tocilizumab and 
rituximab have been studied in this regard, 
but no firm recommendations can be provided 
at this stage.
PPAR-gamma antagonists 
(thiazolidinediones)
These antidiabetic drugs also have anti-
inflammatory properties, e.g. rosiglitazone, 
and have been retrospectively shown to 
be beneficial in AD.[22] They also act by 
improving skin barrier function and thus may 
be more effective as preventive treatment.
Complementary/
alternative therapies 
These treatments may be defined as 
forms of therapy or examination that 
have no scientific basis and for which no 
effective or diagnostic reliability has been 
demonstrated by scientific methods.[23] 
Complementary and alternative medicine 
refers to the phytotherapies (Chinese herbal 
medicines, Japanese herbal medicines 
(Kampo), siddha/ayurveda, tea tree oil 
and essential fatty acids), homoeopathy, 
complementary psychotherapy (hypnosis, 
biofeedback, stress management), acu-
puncture, bioresonance treatment, 
balneotherapy, cleansing of the 
colon with enemas, massage therapy, 
autologous blood therapy, Reiki and 
topical streptococcal application. These 
modalities are becoming increasingly 
popular,[24] which is understandable when 
people are faced with an intractable, 
incurable, highly symptomatic condition 
for which conventional medicine seems to 
be only partially beneficial. Approximately 
30 - 42.5% of patients with allergies 
report the use of complementary treat-
ments in Europe;[23,25] these tend to be 
younger women with a high educational 
background.[24] No reliable figures or 
records of treatment methods exist for the 
treatment of AD by African traditional 
healers. It is important to advise patients 
regarding complementary medicines as 
treatment for AD (Table 3). No benefit 
from probiotics, prebiotics and synbiotics 
has been demonstrated.[26] 
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Table 3. Advice to patients regarding complementary medicines as treatment for atopic 
dermatitis
• The safety and efficacy of therapies such as herbal medicines, homoeopathy, massage and 
food supplements have not been adequately investigated in clinical trials
• Caution should be observed with the use of herbal medicines in children
• Topical corticosteroids are sometimes illegally added to some herbal medications 
• Liver toxicity can occur with the use of some Chinese herbal medicines
• Emollient treatment should continue, even when complementary therapies are being used
• There may be improvement with regular massage with emollients 
• Patients should inform healthcare professionals if they are using complementary therapies
